Observation versus Immediate Re-induction for Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results
ConclusionOur study did not find a statistically significant difference in overall response rates, or survival outcome measures in patients with AML and indeterminate day 14 bone marrow receiving re-induction or not. Our findings question the utility of immediate re-induction chemotherapy and raise concern for over treatment in this patient population. Larger studies investigating similar outcomes are warranted to validate these clinical findings.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Bone Marrow Aspiration and Biopsy | Cancer & Oncology | Chemotherapy | Leukemia | Lymphoma | Myeloma | Statistics | Study